Bispecific T-cell–redirecting antibodies bind to both tumor-associated antigens (TAA) and the signaling components of the T-cell receptor complex, bypassing the normal T-cell receptor–major histocompatibility complex interaction, thus enabling the cytotoxic activity of T cells to be redirected toward the recognized tumor cells. This evidence concerns the gene TBXT and neoplasm.